David Tamang

Preclinical activity, pharmacodynamic, and pharmacokinetic properties of a selective HDAC6 inhibitor, ACY-1215, in combination with bortezomib in multiple myeloma

Loredana Santo, Teru Hideshima, Andrew L. Kung et al. · Blood · 2012 · 601 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +15

Immune epitope database analysis resource

Young‐Hee Kim, Julia Ponomarenko, Zhenggang Zhu et al. · Nucleic Acids Research · 2012 · 517 citations · Full text

Life Sciences, Bioinformatics, Immunology +17

Ricolinostat, the First Selective Histone Deacetylase 6 Inhibitor, in Combination with Bortezomib and Dexamethasone for Relapsed or Refractory Multiple Myeloma

Dan T. Vogl, Noopur Raje, Sundar Jagannath et al. · Clinical Cancer Research · 2017 · 251 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial

Andrew J. Yee, William Bensinger, Jeffrey G. Supko et al. · The Lancet Oncology · 2016 · 199 citations

Medicine, Hematology, Pharmacotherapy +14

Sensitization of Tumor Cells to NK Cell-Mediated Killing by Proteasome Inhibition

William Hallett, Erik Ames, Milad Motarjemi et al. · The Journal of Immunology · 2008 · 137 citations · Full text

Medicine, Immunology, Pharmacology +15